Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zolbetuximab plus SOX or CapeOX for HER2-negative, CLDN18.2-positive advanced gastric or gastroesophageal junction cancer
jRCTs031240510Phase 2Active, not recruiting
- Sponsor
- Astellas Pharma
- Start
- Dec 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of zolbetuximab, oxaliplatin, tegafur and capecitabine in gastric cancer (GC) and gastroesophageal junction adenocarcinoma (2 arms), sponsored by Astellas Pharma. Primary endpoint: 12-month progression-free survival rate. Started Dec 2024; status: active, not recruiting.
02
Drugs
zolbetuximaboxaliplatintegafurcapecitabine
03
Conditions
gastric cancer (GC)gastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on jRCTs031240510.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031240510.